-
2023-507795-51-00
5
2022-05-17
atherosclerotic heart and blood vessel disease (the narrowing of arter
-
2023-506361-56-00
5
2022-04-01
Endometrial cancer
-
2023-509466-38-00
5
2022-03-08
Cancer
-
2023-503640-14-00
5
2022-02-17
Newly diagnosed Philadelphia-negative B-cell precursor Acute Lymphobla
-
2023-509133-39-00
5
2021-11-29
Hormone receptor positive, HER2-negative advanced breast cancer
-
2023-506177-35-00
11
2021-10-23
Ovarian, fallopian tube, or primary peritoneal carcinoma.
-
2023-503441-55-00
4
2021-10-14
Relapsed/Refractory Multiple Myeloma
-
2023-506926-35-00
5
2021-09-24
Atherosclerotic cardiovascular disease, chronic kidney disease and sys
-
2023-508690-92-00
11
2021-09-20
IgA Nephropathy
-
2023-503772-24-00
10
2021-09-15
IgA Nephropathy
-
2022-502100-70-00
10
2021-06-23
Participants with Microsatellite Instability-High (MSI-H) or Mismatch
-
2023-504997-39-00
5
2021-06-14
Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2
-
2023-504684-16-00
5
2021-06-05
follicular lymphoma (FL) and marginal zone lymphoma (MZL)
-
2024-514287-84-00
5
2021-04-28
Multiple sclerosis
-
2023-507961-24-00
5
2021-04-19
High-Risk HER2-Positive Breast Cancer
-
2023-509405-77-00
5
2021-02-16
Colorectal cancer (BRAF V600E-mutant mCRC)
-
2022-500439-35-00
5
2021-02-11
treatment-naive chronic lymphocytic leukemia
-
2023-505936-37-00
6
2021-02-03
Urothelial cancer
-
2023-507338-26-00
5
2021-02-01
Histologically documented gastric or gastroesophageal junction adenoca
-
2024-515404-39-00
5
2021-01-14
Breast cancer
-
2023-504830-23-00
5
2020-12-16
B-cell Lymphoma
-
2024-516653-44-00
5
2020-11-30
HER2-Low, Hormone Receptor Positive Breast Cancer which has Progressed
-
2023-504828-25-00
9
2020-11-16
Chronic Lymphocytic Leukemia
-
2023-505852-23-00
5
2020-11-12
High risk recurrent prostate cancer previously treated with radical pr